2025 / 08 / 25

Exhibition and Presentation at Biologics US 2025


Ajinomoto Bio-Pharma Services will participate in Biologics US 2025, on October 2 to 3, 2025.

Biologics US 2025 brings together leaders in biologics R&D through two focused programs on one dynamic platform. Over two immersive days, the event spotlights breakthrough innovations in proteins, antibodies, and the development of antibody-drug conjugates (ADCs).

At the exhibition booth, the latest technologies and services such as AJICAP® will be introduced.

We look forward to your visit.

Event Name Biologics US 2025
Dates October 2(Thu) – 3 (Fri), 2025
Venue Sheraton San Diego Resort, San Diego, CA
Exhibition [Booth position]   Booth : 1
Exhibitors’ presentation

A Versatile Approach to Generating Next-Generation Antibody Conjugates Through AJICAP® Technologies

Topics and Presenters “Maximizing the performance of antibody conjugates through AJICAPⓇ Technology:
Site-specific Conjugation for flexible DAR control and Linker selectively cleaved in tumor.”
Yusaku Nomura, Ajinomoto Co., Inc.
Executive Summary Antibody-drug conjugates (ADCs) are increasingly being applied to a variety of therapeutic modalities; however, their development and manufacturing still face significant challenges, including “optimization of the drug-to-antibody ratio (DAR)”, “narrow therapeutic windows”, and “stringent quality control requirements”.
AJICAPⓇ Technology provides a comprehensive solution for optimizing antibody-drug conjugates (ADCs) and oligonucleotide conjugates by addressing key challenges such as DAR control, expanding the therapeutic window, and improving stability.
Our site-specific conjugation method uses Fc affinity peptides to generate homogeneous ADCs without redox chemistry or column purification. This enables scalable production of DAR1, DAR2, DAR4, DAR8, DAR10, and dual-payload formats. Over 60 grams of GMP-grade ADCs have been successfully manufactured.
The AJICAPⓇ linker improves plasma stability and hydrophilicity compared to traditional valine-citrulline (VC) linkers, minimizing off-target payload release and enhancing tumor-selective payload cleavage. This expands the therapeutic window and improves the safety profile.
In oligonucleotide conjugates, the DAR1 format enabled by AJICAPⓇ significantly enhances the biological stability and physicochemical properties, demonstrating its potential as a robust therapeutic modality.
AJICAPⓇ is also applicable to next-generation conjugates, including proteins, lipid nanoparticles (LNPs), and PROTACs. We have conducted various in vivo studies to validate the versatility and utility of our platform across multiple modalities.
Date, Time and Venue October 2(Thu), 2025 11:50 ~ 12:15